US20100137424A1 - Pharmaceutical compositions comprising nebivolol or a nebivolol analogue - Google Patents

Pharmaceutical compositions comprising nebivolol or a nebivolol analogue Download PDF

Info

Publication number
US20100137424A1
US20100137424A1 US12/523,686 US52368608A US2010137424A1 US 20100137424 A1 US20100137424 A1 US 20100137424A1 US 52368608 A US52368608 A US 52368608A US 2010137424 A1 US2010137424 A1 US 2010137424A1
Authority
US
United States
Prior art keywords
nebivolol
pharmaceutical composition
wetting agent
polysorbate
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/523,686
Other languages
English (en)
Inventor
Mostafa Akbarieh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Pharmaceuticals ULC
Original Assignee
Mylan Pharmaceuticals ULC
Genpharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Pharmaceuticals ULC, Genpharm Inc filed Critical Mylan Pharmaceuticals ULC
Assigned to GENPHARM, INC. reassignment GENPHARM, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHAH, SHETAL, MOHIDEEN, FAZAL M., AKBARIEH, MOSTAFA
Assigned to GENPHARM ULC reassignment GENPHARM ULC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: GENPHARM, INC.
Assigned to MYLAN PHARMACEUTICALS ULC reassignment MYLAN PHARMACEUTICALS ULC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: GENPHARM ULC
Publication of US20100137424A1 publication Critical patent/US20100137424A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention pertains to the field of pharmaceutical compositions and methods of preparation thereof and, more particularly, to pharmaceutical compositions comprising, as the active medicinal ingredient, nebivolol, a nebivolol analogue or a pharmaceutically acceptable salt thereof and a wetting agent, and to a method of preparation thereof.
  • Nebivolol is the generic name of (( ⁇ ))-(R*(S*(S*-(S*))))-(alpha),(alpha)′-(iminobis(methylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol).
  • the general structure of nebivolol as it's hydrochloride salt is shown as Formula (a).
  • Nebivolol is a ⁇ 1-adrenoceptor blocking drug, or ⁇ -blocker, distinguished from other members of its drug class by its additional nitric oxide (NO)-mediated vasodilatory effects. Consequently, as well as effectively lowering blood pressure by blocking ⁇ 1-adrenoceptors in the heart and vasculature, nebivolol may also slow or blocking ⁇ 1-adrenoceptors in the heart and vasculature, nebivolol may also slow or prevent some of the vascular complications associated with hypertension, by improving arterial compliance and reducing peripheral vascular resistance.
  • NO nitric oxide
  • Nebivolol is described as a mixture of equal amounts of 2 enantiomers having respectively the SRRR- and the RSSS-configuration.
  • the SRRR-configuration is a potent and selective ⁇ 1-adrenergic antagonist both in vitro and in vivo.
  • Nebivolol can be distinguished from other ⁇ -adrenergic antagonists because it acutely lowers blood pressure in spontaneously hypertensive rats, decreases total peripheral vascular resistance and augments stroke volume in anaesthetised dogs. These haemodynamic effects are largely attributable to the RSSS-configuration of nebivolol.
  • RSSS-nebivolol is a potentiator for a series of antihypertensive agents such as atenolol, propanolol, prazosin, hydralazine and, interestingly, also its own enantiomer, i.e., the SRRR-configuration.
  • Several clinical trials have also demonstrated the therapeutic potential of nebivolol as a ⁇ 1-selective beta-blocker and antihypertensive agent.
  • Nebivolol as it's hydrochloride salt is available in a tablet dosage form and sold in the UK as Nebilet® for the treatment of mild to moderate essential hypertension in humans.
  • Nebivolol and pharmaceutically acceptable salts are described generally in EP 0 145 067 and more specifically in EP 0 334 429 which are incorporated herein by reference.
  • EP 0 145 067 generally describes 2,2′-iminobisethanol derivatives useful for the treatment and/or prevention of disorders of the coronary vascular system.
  • EP 0 334 429 describes (iminobismethylene)bis(3,4-dihydro-2H-1-benzopyran-2-methanol)derivatives including nebivolol and pharmaceutically acceptable salts.
  • Nebivolol has basic properties it may be converted into its pharmaceutically acceptable acid addition salt forms by treatment with appropriate acids.
  • Appropriate acids are, for example, inorganic acids, such as the hydrochloride or hydrobromide.
  • EP 0 744 946 B1 by Eugeen et al discloses suitable solid and semi-solid pharmaceutical compositions comprising inter alia nebivolol and pharmaceutically acceptable salts for use as antihypertensive agents.
  • Dosage forms include powders, pills, capsules, tablets, suppositories, creams, gels, ointments. Tablets are a particularly preferred solid oral dosage form.
  • the specification describes that oral administration of nebivolol hydrochloride was impeded by the poor dissolution when in a “normal” crystalline form.
  • a very important factor influencing the bioavailability of active ingredients after oral administration is the dissolution or, more particularly, the rate of dissolution of the active ingredient or drug substance, particularly in gastric fluid. It is recognized in the art that the dissolution for solid dosage forms, particularly tablets, should amount to at least 75% in 45 minutes in 0.1M Hydrochloric acid at a temperature of 37° C. as measured according to test procedures described in the official pharmacopoeias known to those skilled in the art, e.g., the U.S. Pharmacopoeia XXII.
  • EP 0 744 946 teaches that the specific area of the micronized material is at least about 23 ⁇ 10 3 cm 2 /g (2.3 ⁇ 10 3 m 2 /kg), preferably more than 25 ⁇ 10 3 cm 2 /g (2.5 ⁇ 10 3 m 2 /kg), more preferably more than 28 ⁇ 10 3 cm 2 /g (2.8 ⁇ 10 3 m 2 /kg), and most preferably more than 31 ⁇ 10 3 cm 2 /g (3.1 ⁇ 10 3 m 2 /kg).
  • the micronized material was described in the following way; at most 50% of the particles may have a diameter larger than 10 ⁇ m, i.e. the DL 50 has a maximum value of 10 ⁇ m.
  • the DL 50 should amount to less than 8 ⁇ m. At most 10% of the particles may have a diameter larger than 20 ⁇ m, i.e. the DL 10 has a maximum value of 20 ⁇ m.
  • the DL 10 should amount to less than 18 ⁇ m.
  • nebivolol hydrochloride in an oral dosage form was apparently improved by formulating micronized material with a wetting agent where the ratio (w/w) of wetting agent/active ingredient ranged between 0.025 and 0.5.
  • the invention disclosed in EP 0 744 946 emphasized that in order to achieve the required pharmacopoeial dissolution, the nebivolol hydrochloride needed to be micronized and sufficiently wet. Wetting was achieved through the inclusion of a wetting agent within the aforesaid ratio. This ratio was described as being an important factor because on the one hand the percentage level of wetting agent needs to be sufficient to influence the desired dissolution but not at the expense of undesirable tablet hardness that affects production on a commercial scale. When the level of wetting agent is too high, resulting tablets do not have the appropriate hardness. Additionally it is known in the art that high levels of wetting agents in pharmaceutical formulations are linked to undesirable effects in humans e.g.
  • Micronization as used herein is a generic term for the process where the mean particle size of a particular drug substance is reduced by mechanical means which increases the surface area of the particles available for contact with biological fluids. Micronization can be carried out by known techniques such as milling or sieving through appropriate sieves; see Pharmaceutical Dosage Forms: Vol 2, 1990; H A Lieberman, page 107. However, these techniques are time consuming and uneconomic when the objective is to prepare pharmaceutical dosage forms comprising nebivolol hydrochloride on a commercial scale that also complies with rigorous internal and external quality control requirements.
  • WO 2006/025070 to Sheth R et al and incorporated herein discloses inter alia pharmaceutical compositions comprising nebivolol hydrochloride e.g., tablets and capsules without using a wetting agent.
  • An object of the present invention is to provide a pharmaceutical composition comprising nebivolol or a nebivolol analogue.
  • a pharmaceutical composition for oral administration comprising an active ingredient and a wetting agent, wherein the active ingredient is nebivolol, a nebivolol analogue or a pharmaceutically acceptable salt thereof, the wetting agent is not colloidal silicon dioxide and the ratio (w/w) of wetting agent to active ingredient is less than 0.025.
  • the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of nebivolol is the hydrochloride salt.
  • the pharmaceutical composition is characterized in that the nebivolol hydrochloride is unmicronized.
  • the pharmaceutical composition is characterized in that the wetting agent consists of a polysorbate.
  • the pharmaceutical composition is characterized in that the polysorbate is polysorbate 80.
  • the pharmaceutical composition is characterized in that the pharmaceutically acceptable carrier is selected from; a filler, a binder, a disintegrant, a lubricant and a glidant or mixtures thereof.
  • the pharmaceutical composition is characterized in that the pharmaceutically acceptable salt of nebivolol is the hydrochloride salt, the wetting agent is polysorbate 80, the filler is a spray dried mixture of microcrystalline cellulose and lactose and/or lactose monohydrate, the binder is hydroxypropylmethylcellulose, the disintegrant is corn starch and/or croscarmellose sodium, the lubricant is magnesium stearate and the glidant is colloidal silicon dioxide.
  • the pharmaceutically acceptable salt of nebivolol is the hydrochloride salt
  • the wetting agent is polysorbate 80
  • the filler is a spray dried mixture of microcrystalline cellulose and lactose and/or lactose monohydrate
  • the binder is hydroxypropylmethylcellulose
  • the disintegrant is corn starch and/or croscarmellose sodium
  • the lubricant is magnesium stearate
  • the glidant is colloidal silicon dioxide.
  • the pharmaceutical composition comprises, on a weight percentage basis, from about 0.5% to about 10% of nebivolol or a pharmaceutically acceptable salt, from about 0.01% to about 0.04% of a wetting agent, from about 20% to about 80% of a filler, from about 1% to about 4% of a binder, from about 2% to about 30% of a disintegrant, from about 0.25% to about 2% of a lubricant and from about 0.1% to about 2% of a glidant.
  • the pharmaceutical composition is in the form of a tablet.
  • the pharmaceutical composition in the form of a tablet exhibits a dissolution of at least 75% after 45 minutes.
  • a process for the preparation of a pharmaceutical composition for oral administration comprising an active ingredient and a wetting agent, wherein the active ingredient is nebivolol, a nebivolol analogue or a pharmaceutically acceptable salt thereof, the wetting agent is not colloidal silicon dioxide and the ratio (w/w) of wetting agent to active ingredient is less than 0.025.
  • the process comprises: (a) combining the active ingredient in intimate admixture with one or more pharmaceutically acceptable carriers; and (b) optionally compressing the mixture from step (a) into a tablet.
  • step (a) of the process includes wet granulation.
  • a pharmaceutical composition comprising nebivolol or a pharmaceutical composition for oral administration comprising an active ingredient and a wetting agent, wherein the active ingredient is nebivolol, a nebivolol analogue or a pharmaceutically acceptable salt thereof, the wetting agent is not colloidal silicon dioxide and the ratio (w/w) of wetting agent to active ingredient is less than 0.025, for the treatment of coronary vascular disorders in humans.
  • compositions comprising nebivolol hydrochloride
  • nebivolol hydrochloride The person skilled in the art of developing pharmaceutical compositions comprising nebivolol hydrochloride is faced with the dual problem of ensuring nebivolol has an acceptable dissolution in biological media whilst at the same time ensuring the composition facilitates production on an industrial scale and can satisfy the rigorous requirements of internal and external quality control.
  • compositions that meet these objectives and that solve the hitherto known drawbacks of dissolution of nebivolol hydrochloride by using a lower ratio of wetting agent to active ingredient than employed in EP 0 744 946. Moreover, it was surprisingly found that as a result of the use of the lower ratio of wetting agent to active ingredient it was not necessary to micronize the active ingredient, thereby making the composition and process for production more economical.
  • oral dosage forms comprising nebivolol, nebivolol analogues or pharmaceutically acceptable salts thereof can be prepared which exhibit excellent dissolution in compliance with pharmacopoeial standards known to those in the art using a wetting agent, where the ratio (w/w) of wetting agent/active ingredient is less than 0.025. This is particularly demonstrated herein using pharmaceutical compositions comprising nebivolol hydrochloride as the active ingredient.
  • the active ingredient in the compositions of the present invention is nebivolol, a nebivolol analogue or a pharmaceutically acceptable salt thereof.
  • nebivolol analogue refers to compounds that are structurally similar to nebivolol and exhibit a similar pharmaceutical activity.
  • the nebivolol analogue is a ⁇ 1 receptor antagonist.
  • nebivolol analogues that are suitable for incorporation in the composition of the present invention include, but are not limited to, metipranolol, nadolol, oxprenolol, penbuolol, pindolol, propanolol, tertatolol, timolol, sotalol, atenolol, acebutolol, celiprolol, betaxolol, bisoprolol, esmolol and metoprolol.
  • the present invention is particularly described using reference to nebivolol hydrochloride, however, a worker skilled in the art would readily appreciate that the present invention is not limited to compositions containing nebivolol hydrochloride.
  • salts with appropriate acids are, for example, inorganic acids, such as a hydrohalic acid, e.g. hydrochloric, hydrobromic, and sulfuric acid, nitric acid, phosphoric acid; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, ethanedioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-2-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzo
  • inorganic acids such as a hydrohalic acid,
  • the active ingredient for example, nebivolol or a pharmaceutically acceptable salt thereof, is typically present within the composition at a concentration of about 0.5% by weight to about 10% by weight of the composition.
  • the final concentration of active ingredient is selected based on the required dosage of the active ingredient.
  • the active ingredient used in the compositions of the present invention can be unmicronized.
  • the term “unmicronized” refers to solid particles of nebivolol or pharmaceutically acceptable salts, preferably the hydrochloride salt which exhibit a specific surface area of less than about 23 ⁇ 10 3 cm 2 /g (2.3 ⁇ 10 3 m 2 /kg).
  • compositions of the present invention do not require that the active ingredient be micronized, the active ingredient can be micronized prior to formulation in a composition of the present invention.
  • compositions of the present invention comprise a wetting agent.
  • wetting agent means a compound used to aid in attaining intimate contact between solid particles and liquids.
  • Useful wetting agents include by way of example and without limitation, gelatin, casein, lecithin (phosphatides), gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters or polysorbates (e.g., TWEEN®), polyethylene glycols, polyoxyethylene stearates, phosphates, sodium lauryl sulphate, poloxamer, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxyl propylcellulose, hydroxypropylmethylcellulose phthalate, non
  • colloidal silicon dioxide is sometimes found to exhibit wetting agent properties, when used in the compositions of the present invention, the colloidal silicon dioxide is acting as a glidant (see discussion below) and not as a wetting agent.
  • the wetting agent is a polysorbate, more preferably polysorbate 80.
  • the preferred weight range of the polysorbate is from about 0.01% to about 0.04% by weight with about 0.03% being particularly preferred.
  • the ratio (w/w) of wetting agent to active ingredient must always be less than 0.025.
  • compositions of the present invention can also contain one or more pharmaceutically acceptable adjuvants or excipients.
  • pharmaceutically acceptable excipients for use in the compositions of the present invention include, but are not limited to, fillers, glidants, lubricants, diluents, binders, disintegrants, carriers, colorants, coatings and the like, and mixtures thereof, that are typically used in the art for preparation of oral solid dosage forms.
  • filler is intended to mean inert substances used as fillers to create the desired bulk, flow properties, and compression characteristics in the preparation of tablets and capsules.
  • Useful fillers or diluents may be inert fillers, either water soluble or water insoluble and selected from those typically used in the pharmaceutical art for oral solid dosage forms.
  • Suitable fillers include, but are not limited to, calcium carbonate, dicalcium phosphate, tricalcium phosphate, microcrystalline cellulose, monosaccharide, disaccharides, polyhydric alcohols, sucrose, dextrose, lactose, mannitol, sorbitol, alone or mixtures thereof and the like or mixtures thereof.
  • Particularly preferred fillers within the scope of the invention are lactose, even more preferred lactose monohydrate and spray dried mixtures of microcrystalline cellulose and lactose e.g. sold under the trade name Microcelac® These fillers can be used alone or in combination.
  • the preferred percentage by weight range either alone or in combination within the scope of the invention is about 20% by weight to about 80% by weight.
  • lubricant is intended to mean substances used in tablet formulations to reduce friction during tablet compression.
  • Useful lubricants include, by way of example and without limitation, calcium stearate, magnesium stearate, mineral oil, stearic acid, zinc stearate, combinations thereof and other such materials known to those of ordinary skill in the art.
  • the preferred lubricant is magnesium stearate.
  • the preferred weight range of magnesium stearate is from about 0.25% to about 2% by weight with about 0.5% being particularly preferred.
  • disintegrant is intended to mean a compound used in solid dosage forms to promote the disruption of the solid mass into smaller particles which are more readily dispersed or dissolved.
  • Useful disintegrants include, by way of example and without limitation, starches such as corn starch, potato starch, pre-gelatinized and modified starched thereof, sweeteners, clays, such as bentonite, microcrystalline cellulose (e.g. Avicel®), Crospovidone, carsium (e.g. Amberlite), alginates, sodium starch glycolate, gums such as agar, guar, locust bean, karaya, pectin, tragacanth, combinations thereof and other such materials known to those of ordinary skill in the art.
  • starches such as corn starch, potato starch, pre-gelatinized and modified starched thereof, sweeteners, clays, such as bentonite, microcrystalline cellulose (e.g. Avicel®), Crospovidone, carsium (e.g. Amberlite), alginates, sodium starch glycolate
  • the preferred disintegrants are Croscarmellose sodium and Corn starch either alone or in combination.
  • the preferred weight ranges of these disintegrants alone are from about 2% to about 30%.
  • Corn starch is optimally used at about 20% by weight and the Croscarmellose sodium within the range of about 2% to about 3% by weight of the composition.
  • binders is intended to mean substances used to cause adhesion of powder particles in tablet granulations.
  • Useful binders within the scope of the invention include the following non limiting examples e.g. starch, poly(ethylene glycol), guar gum, polysaccharide, bentonites, sugars, invert sugars, poloxamers (PLURONIC F68®, PLURONIC F127®), collagen, albumin, celluloses e.g. hydroxypropylmethylcellulose, combinations thereof and the like.
  • binders include, for example, poly(propylene glycol), polyoxyethylene-polypropylene copolymer, polyethylene ester, polyethylene sorbitan ester, poly(ethylene oxide), microcrystalline cellulose, polyvinylpyrrolidone, combinations thereof and other such materials known to those of ordinary skill in the art.
  • the preferred binder within the scope of the invention is hydroxypropylmethylcellulose.
  • the preferred weight range of hydroxypropylmethylcellulose is from about 1% to about 4% by weight of the composition.
  • glidant is intended to mean agents used in tablet and capsule formulations to improve flow-properties during tablet compression and to produce an anti-caking effect.
  • Useful glidants may be any glidant typically used in the pharmaceutical art for oral solid dosage forms. Examples include, but are not limited to, colloidal silicon dioxide.
  • the preferred glidant is colloidal silicon dioxide.
  • the preferred weight range is from about 0.1% to about 2.0% by weight, based on the total weight of the composition.
  • Oral administration is the generally preferred route for administration of compositions within the scope of the invention since this route is particularly convenient and acceptable to patients. Accordingly, a preferred embodiment of the present invention provides tablets prepared from the compositions of the present invention.
  • Tablets according to the present invention may be produced by any standard tabletting technique, e.g. by wet granulation, dry granulation or direct compression as described in Lachman and Liebermann second edition. For example, by granulating the active component with or without an excipient, followed by addition of any other excipient(s) and then compression to form a tablet.
  • the tablets are preferably made by wet granulation methods as are known in the art; Lachman & Lieberman, Pharmaceutical Dosage Forms: Tablets, Vol 2, second edition, 1990, page 7. This may be carried out by blending the active ingredient with one or more pharmaceutically acceptable adjuvants, adding a granulation liquid to form a granulate, optionally drying the granulate and compressing the material into tablets.
  • a preferred embodiment of the present invention provides a pharmaceutical composition comprising nebivolol or a pharmaceutically acceptable salt thereof.
  • effective doses for the treatment of coronary vascular disorders in humans and in particular, conditions associated with the treatment of mild to moderate essential hypertension will lie in the range of about 0.1 to about 50 mg, most preferably about 1 to about 10 mg, for example about 5 mg of the active ingredient per unit dose which could be administered in single or divided doses, for example, 1 to 4 times per day.
  • the safe and effective amount of the compositions of the present invention will vary depending on the age and physical condition of the patient being treated, the severity of the condition, the duration of treatment and other factors within the purview of the skilled physician.
  • compositions prepared in accordance with example 1 were compared with reference samples of NEBILET® 5 mg (marketed by A. Menarini Pharmaceuticals UK Ltd).
  • the test method and parameters are described more fully below.
  • the time points for sampling were at 15 minutes, 30 minutes and 45 minutes.
  • 900 ml of 0.1M Hydrochloric acid was used as the test solution.
  • the aliquots of nebivolol sampled at each time point were injected into a standard High Performance Liquid Chromatography column equipped with an Ultra Violet detector.
  • the samples were quantified against a standard of known concentration based on the sample versus standard peak response.
  • the dissolution specification required was at least 75% after 45 minutes.
  • Dissolution Equipment and Parameters Method Apparatus II (Paddles) Speed: 50 rpm Dissolution Medium: 0.1 N HCl Volume: 900 mL Run Time: 45 minutes Temperature: 37° C. ⁇ 0.5° C. HPLC Equipment and Parameters Column: Ace 3 Phenyl, 150 mm ⁇ 4.6 mm, 3 ⁇ m Flow Rate: 1.2 mL/min Injection Volume: 40 ⁇ L Run Time: 15 minutes Wavelength: 283 nm Column Temperature: 30° C.
  • Nebivolol HCl Equivalent to 22 mg of Nebivolol
  • Inject Standard Working Solution 1 five times. Calculate the relative standard deviation (RSD), tailing factor (T), and number of theoretical plates (N). The RSD is not more than 2.0%, T is not more than 1.5 and N is not less than 10000.
  • Tablet # 15 min 30 min 45 min 5 mg tablet from Example 1 1 88.54% 98.27% 99.04% 2 89.43% 98.01% 100.30% 3 87.40% 97.04% 99.81% 4 89.46% 98.89% 101.10% 5 94.32% 101.92% 103.16% 6 96.49% 100.92% 101.47% Average 90.94% 99.18% 100.81% 5 mg NEBILET ® (marketed by A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US12/523,686 2007-01-22 2008-01-22 Pharmaceutical compositions comprising nebivolol or a nebivolol analogue Abandoned US20100137424A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2575527 2007-01-22
CACA2,575,527 2007-01-22
PCT/CA2008/000119 WO2008089549A1 (en) 2007-01-22 2008-01-22 Pharmaceutical compositions comprising nebivolol or a nebivolol analogue

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2008/000119 A-371-Of-International WO2008089549A1 (en) 2007-01-22 2008-01-22 Pharmaceutical compositions comprising nebivolol or a nebivolol analogue

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/704,375 Continuation US10117939B2 (en) 2007-01-22 2015-05-05 Pharmaceutical compositions comprising nebivolol or a nebivolol analogue

Publications (1)

Publication Number Publication Date
US20100137424A1 true US20100137424A1 (en) 2010-06-03

Family

ID=39644046

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/523,686 Abandoned US20100137424A1 (en) 2007-01-22 2008-01-22 Pharmaceutical compositions comprising nebivolol or a nebivolol analogue
US14/704,375 Expired - Fee Related US10117939B2 (en) 2007-01-22 2015-05-05 Pharmaceutical compositions comprising nebivolol or a nebivolol analogue

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/704,375 Expired - Fee Related US10117939B2 (en) 2007-01-22 2015-05-05 Pharmaceutical compositions comprising nebivolol or a nebivolol analogue

Country Status (6)

Country Link
US (2) US20100137424A1 (enExample)
EP (1) EP2124931A4 (enExample)
JP (1) JP5448844B2 (enExample)
AU (1) AU2008209264B2 (enExample)
CA (1) CA2675538C (enExample)
WO (1) WO2008089549A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
US20220016025A1 (en) * 2020-07-08 2022-01-20 Vinayak Dinesh DENDUKURI Formulations of nebivolol

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338732A (en) * 1991-06-18 1994-08-16 Bristol-Myers Squibb Company Megestrol acetate formulation
US5759580A (en) * 1994-02-17 1998-06-02 Janssen Pharmaceutica, N.V. Compositions containing micronized nebivolol
US6410054B1 (en) * 1998-12-09 2002-06-25 G. D. Searle & Co. Immediate release eplerenone compositions
US20030114461A1 (en) * 2000-05-31 2003-06-19 Frederic Galli 1,4-Diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
WO2005117899A1 (en) * 2004-06-02 2005-12-15 Cipla Limited Pharmaceutical composition comprising tibolone and process for procuding the same
US20070259950A1 (en) * 2004-07-30 2007-11-08 Torrent Pharmaceuticals Limited Nebivolol and Its Pharmaceutically Acceptable Salts, Process for Preparation and Pharmaceutical Compositions of Nebivolol

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
CA1337432C (en) 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
JPH098913A (ja) 1995-06-22 1997-01-10 Hitachi Maxell Ltd 情報通信システム
WO2005099699A1 (en) 2004-04-07 2005-10-27 Sepracor Inc. Combination of (s)-amlodipine and a beta-blocker, and methods for reducing hypertension
EP1850842A1 (de) 2005-02-11 2007-11-07 Stada Arzneimittel Ag Pharmazeutische zusammensetzungen nebivolo und ein hydrophiles polymer
CA2610694A1 (en) * 2005-05-31 2006-12-07 Mylan Laboratories, Inc. Compositions comrising nebivolol
EP1839658A1 (en) * 2006-03-30 2007-10-03 Hexal A/S Pharmaceutical composition comprising micronized nebivolol

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338732A (en) * 1991-06-18 1994-08-16 Bristol-Myers Squibb Company Megestrol acetate formulation
US5759580A (en) * 1994-02-17 1998-06-02 Janssen Pharmaceutica, N.V. Compositions containing micronized nebivolol
US6410054B1 (en) * 1998-12-09 2002-06-25 G. D. Searle & Co. Immediate release eplerenone compositions
US20030114461A1 (en) * 2000-05-31 2003-06-19 Frederic Galli 1,4-Diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
WO2005117899A1 (en) * 2004-06-02 2005-12-15 Cipla Limited Pharmaceutical composition comprising tibolone and process for procuding the same
US20070259950A1 (en) * 2004-07-30 2007-11-08 Torrent Pharmaceuticals Limited Nebivolol and Its Pharmaceutically Acceptable Salts, Process for Preparation and Pharmaceutical Compositions of Nebivolol

Also Published As

Publication number Publication date
AU2008209264B2 (en) 2014-11-27
EP2124931A4 (en) 2013-08-28
JP2010516712A (ja) 2010-05-20
WO2008089549A1 (en) 2008-07-31
JP5448844B2 (ja) 2014-03-19
CA2675538A1 (en) 2008-07-31
EP2124931A1 (en) 2009-12-02
US10117939B2 (en) 2018-11-06
CA2675538C (en) 2017-02-28
AU2008209264A1 (en) 2008-07-31
US20150231261A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
AU2006295440B2 (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
EP2068839B1 (en) Pharmaceutical compositions comprising nilotinib or its salt
US8900605B2 (en) Solid ivabradine-containing composition
RU2489149C2 (ru) Стабилизированные аморфные формы иматиниба мезилата
SK283250B6 (sk) Farmaceutická kompozícia, tableta tvoriaca túto farmaceutickú kompozíciu a mikromletá forma hydrochloridu nebivololu
EP1381358B1 (en) Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
CA2760085A1 (en) Oral formulations of bendamustine
US10940135B2 (en) Paclitaxel pharmaceutical composition and pharmaceutical preparation thereof, preparation process and use thereof
EP2482803B1 (en) Formulations for c-met kinase inhibitors
KR20210125994A (ko) 비정질 스파르센탄 조성물
US10117939B2 (en) Pharmaceutical compositions comprising nebivolol or a nebivolol analogue
WO2000004880A1 (en) A wet granulation method for preparing a stable pharmaceutical formulation
US20250340515A1 (en) Cabozantinib compositions and methods of use
JPH1192369A (ja) 医薬品調製物、その製造方法及びシランセトロンの安定化のための酸性添加剤の使用
ES2663721T3 (es) Formulaciones de olmesartán
EP2600839B1 (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine
KR102301743B1 (ko) 에피나코나졸 경구용 조성물
AU2006257428B2 (en) Oral solid pharmaceutical formulation of the tubulin inhibitor indibulin
EP4431088A1 (en) Pharmaceutical compositions comprising dapagliflozin and metformin
US20230293514A1 (en) Injectable depot formulation comprising cariprazine free base particles
KR20190064208A (ko) 피마살탄을 포함하는 고체 분산체
KR20170083484A (ko) 용출률이 개선된 네비보롤을 포함하는 약학적 조성물
KR20160082170A (ko) 리바록사반 함유 경구용 고형제제

Legal Events

Date Code Title Description
AS Assignment

Owner name: GENPHARM, INC.,CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AKBARIEH, MOSTAFA;MOHIDEEN, FAZAL M.;SHAH, SHETAL;SIGNING DATES FROM 20080208 TO 20080213;REEL/FRAME:023684/0623

Owner name: GENPHARM ULC,CANADA

Free format text: CHANGE OF NAME;ASSIGNOR:GENPHARM, INC.;REEL/FRAME:023684/0639

Effective date: 20071212

Owner name: MYLAN PHARMACEUTICALS ULC,CANADA

Free format text: CHANGE OF NAME;ASSIGNOR:GENPHARM ULC;REEL/FRAME:023688/0795

Effective date: 20090424

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION